COLL COLLEGIUM PHARMACEUTICAL, INC
FY2025 10-K
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Commercializes differentiated biopharmaceutical products for ADHD and moderate to severe pain in the U.S.
- • New: September 2024 acquisition of Ironshore adds Jornay PM, expanding into neuropsychiatry and ADHD market
Management Discussion & Analysis
- • Revenue $780.6M in 2025, up $149.2M YoY from $631.4M; Jornay PM +$111.7M, Nucynta Products +$19.8M, Belbuca +$10.4M, Xtampza ER +$8.0M
- • Gross profit $463.3M vs $377.3M; operating expenses $284.8M vs $210.4M; operating income $179.6M vs $169.9M; operating margin ~23.0% vs ~26.9% (calculated from operating income/revenue)
Risk Factors
- • Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities
- • Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years
Get deeper insights on COLLEGIUM PHARMACEUTICAL, INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.